Pyopen

• Anti-Bacterial Agents
• ATC:J01CA03

• Carbenicilina [INN-Spanish]
• Carbenicillina [DCIT]
• Carbenicilline [INN-French]
• Carbenicillinfree base
• Carbenicillinum [INN-Latin]
• Carboxybenzylpenicillin
• Carboxybenzylpenicillin acid
• Geocillin
• Geopen
• Pyopen
• alpha-Carboxybenzylpencillin

• No information avaliable

C₁₇H₁₈N₂O₆S

http://www.rxlist.com/cgi/generic3/geocillin.htm

Pyopen MSDS

No information avaliable

378.401 g/mol

No information avaliable

451 mg/L

Solid

1.216

Tablets containing 382 mg carbenicillin (for oral use)

For the treatment of acute and chronic infections of the upper and lower urinary tract and in asymptomatic bacteriuria due to susceptible strains of bacteria.

Carbenicillin is a semisynthetic penicillin. Though carbenicillin provides substantial in vitro activity against a variety of both gram-positive and gram-negative microorganisms, the most important aspect of its profile is in its antipseudomonal and antiproteal activity. Because of the high urine levels obtained following administration, carbenicillin has demonstrated clinical efficacy in urinary infections due to susceptible strains of: Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii, Pseudomonas species, Providencia rettgeri, Enterobacter species, and Enterococci (S. faecalis).

Acid stable, and rapidly absorbed from the small intestine following oral administration.

Carbenicillin blood levels achievable are very low, and toxic reactions as a function of overdosage should not occur systematically. The oral LD₅₀ in mice is 3,600 mg/kg, in rats 2,000 mg/kg, and in dogs is in excess of 500 mg/kg. The lethal human dose is not known. Symptoms of overdose include diarrhea, nausea, stomach upset, and vomiting.

No information avaliable

Enteric bacteria and other eubacteria